Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)

Harmony Biosciences Holdings (HRMY) has disclosed Finished Goods for 2 consecutive years, with $2.8 million as the latest value for Q4 2024.

  • Quarterly Finished Goods rose 21.11% to $2.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2024, up 21.11% year-over-year, with the annual reading at $2.8 million for FY2024, 21.11% up from the prior year.
  • Finished Goods hit $2.8 million in Q4 2024 for Harmony Biosciences Holdings, down from $3.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.3 million in Q3 2024 to a low of $2.3 million in Q4 2023.